146 related articles for article (PubMed ID: 38375926)
1. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
Gangat N; Tefferi A
Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
[TBL] [Abstract][Full Text] [Related]
2. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
Patel SA
Br J Haematol; 2024 Apr; 204(4):1137-1138. PubMed ID: 38339780
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
4. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
[No Abstract] [Full Text] [Related]
5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
6. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
[No Abstract] [Full Text] [Related]
7. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.
Vazquez R; Breal C; Zalmai L; Friedrich C; Almire C; Contejean A; Barreau S; Grignano E; Willems L; Deau-Fischer B; Franchi P; Vignon M; Decroocq J; Birsen R; Goldwirt L; Kaltenbach S; Couronne L; Fontenay M; Kosmider O; Bouscary D; Chapuis N
Blood Cancer J; 2021 Mar; 11(3):62. PubMed ID: 33741892
[No Abstract] [Full Text] [Related]
9. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
Kennedy VE; Hui G; Azenkot T; Gaut D; Wieduwilt MJ; Oliai C; Jonas BA; Mittal V; Logan AC; Muffly LS; Mannis GN
Am J Hematol; 2022 Jun; 97(6):E191-E194. PubMed ID: 35266185
[No Abstract] [Full Text] [Related]
10. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Jonas BA; DiNardo C; Fracchiolla N; Pristupa A; Ishizawa K; Jin J; Konopleva M; Ofran Y; Montesinos P; Kovacsovics T; Jang JH; Kantarjian H; Duan Y; Potluri J; Werner M; Pratz KW
Am J Hematol; 2022 Nov; 97(11):E422-E425. PubMed ID: 36053878
[No Abstract] [Full Text] [Related]
11. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
Gangat N; Johnson I; McCullough K; Farrukh F; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Tefferi A
Haematologica; 2022 Oct; 107(10):2501-2505. PubMed ID: 35770533
[No Abstract] [Full Text] [Related]
13. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Bewersdorf JP; Giri S; Wang R; Williams RT; Tallman MS; Zeidan AM; Stahl M
Haematologica; 2020 Nov; 105(11):2659-2663. PubMed ID: 33131256
[No Abstract] [Full Text] [Related]
14. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
[No Abstract] [Full Text] [Related]
15. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
16. Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
Jamy O; Lin K; Worth S; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R
Br J Haematol; 2022 Aug; 198(3):e35-e37. PubMed ID: 35509246
[No Abstract] [Full Text] [Related]
17. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
[No Abstract] [Full Text] [Related]
18. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
19. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
[No Abstract] [Full Text] [Related]
20. To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
Sevindik OG; Mergen M; Mergen S; Mutlu YG; Aydın BB; Serin I
Ann Hematol; 2022 Nov; 101(11):2545-2547. PubMed ID: 35906348
[No Abstract] [Full Text] [Related]
[Next] [New Search]